# Myung‐Ju Ahn
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/myung-ju-ahn/
## Facts
| Field | Value |
| --- | --- |
| Citations | 74,402 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 110 |
| i10-index | 540 |
| Last Known Institution | Samsung Medical Center |
| OpenAlex ID | https://openalex.org/A5034739279 |
| ORCID iD | 0000-0002-5740-9654 |
| Works | 1,304 |
## Researcher papers
Showing 12 of 40.
- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/)
- [AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/azd9291-in-egfr-inhibitor-resistant-non-small-cell-lung-cancer/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma](https://scholariq.org/papers/single-cell-rna-sequencing-demonstrates-the-molecular-and-cellular-reprogramming/)
- [Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-oesophageal-squamous/)
- [Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-multitargeted-pan-trk-ros1-and-alk/)
- [First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung](https://scholariq.org/papers/first-signal-first-line-single-agent-iressa-versus-gemcitabine-and-cisplatin/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
## Researcher university
- [Samsung Medical Center](https://scholariq.org/institutions/samsung-medical-center/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.